550 related articles for article (PubMed ID: 25134325)
1. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
Sandler S
Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
[TBL] [Abstract][Full Text] [Related]
2. [Multimodality therapy for adenocarcinoma of the esophagogastric junction].
He J; Huang JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Sep; 15(9):877-80. PubMed ID: 22990915
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness in esophagogastric cancer.
Knab LM; Belotte J; Munshi HG; Bentrem DJ
Cancer Treat Res; 2015; 164():121-42. PubMed ID: 25677022
[TBL] [Abstract][Full Text] [Related]
4. Treatment approaches to esophagogastric junction tumors.
Kurokawa Y; Sasako M; Doki Y
Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
[TBL] [Abstract][Full Text] [Related]
5. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
Wilke H; Lordick F; Meyer HJ; Stahl M
Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?
Gronnier C; Piessen G; Mariette C
J Visc Surg; 2012 Feb; 149(1):e23-33. PubMed ID: 22341763
[TBL] [Abstract][Full Text] [Related]
9. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?
Moorcraft SY; Smyth EC; Cunningham D
Gastric Cancer; 2015 Jan; 18(1):1-10. PubMed ID: 24638977
[TBL] [Abstract][Full Text] [Related]
11. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
12. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
13. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
[TBL] [Abstract][Full Text] [Related]
14. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant treatment for esophagogastric junction cancer].
Kurokawa Y; Takiguchi S; Miyazaki Y; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Mori M; Doki Y
Nihon Geka Gakkai Zasshi; 2015 Jan; 116(1):50-4. PubMed ID: 25842814
[TBL] [Abstract][Full Text] [Related]
16. Cancer of the gastroesophageal junction: combined modality therapy.
Ilson DH
Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
[TBL] [Abstract][Full Text] [Related]
17. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
18. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].
Ben Salah H; Bahri M; Dhouib F; Daoud J
Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531
[TBL] [Abstract][Full Text] [Related]
19. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma.
Birla R; Hoara P; Caragui A; Cristian M; Constantinoiu S
Chirurgia (Bucur); 2018; 113(1):38-45. PubMed ID: 29509530
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.
Lagarde SM; ten Kate FJ; Reitsma JB; Busch OR; van Lanschot JJ
J Clin Oncol; 2006 Sep; 24(26):4347-55. PubMed ID: 16963732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]